BioWorld

July 31, 2003

ILEX Raises $93.5M In Secondary Public Offering Of Common Stock

ILEX Oncology Inc. gained gross proceeds of $93.5 million through the sale of 5.5 million common shares priced at $17 apiece. (BioWorld Today) Read More

If Passed, BIOFIX Would Fix Broken Tax Code For Biotechs

The Six-Country WHO Network Hands Down Its Final Verdict: Coronavirus Is Behind SARS

BioAxone Making Progress In Spinal Cord Injuries, Cancer

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

Mechanism underlying so-called idiopathic autism inception unveiled

BioWorld Science

Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...